glp 1 and ketogenic diet Could a keto replace diabetes meds? New research explores the possibilities Is the Keto Diet Safe

Sleep itself is metabolic medicine

Most recently, GLP-1 receptor agonists have dominated headlines for their dual benefits in glycemic control and weight reduction, but the broader market is undergoing significant shifts

2-9 They do this by: Building confidence and self-efficacy by empowering patients to actively engage with their treatment journey Educating patients to address the widespread misconception that obesity is not a disease, with 40% of patients unaware of this and 80% feeling solely responsible for their condition Implementing a whole-health approach to redefine treatment success, focus on overall health outcomes, not just weight loss Setting realistic expectations which prepares patients for the possibility of losing less weight than expected while still achieving significant health benefits Supporting medication adherence by providing tools for reminders, routines, titration guidance, and addressing injection anxiety Driving medication persistence as a result of setting realistic expectations and frame treatment around long-term health gains rather than short-term weight loss Mitigating side effects through equipping patients to self-manage common side effects through proactive tracking and helping them connect the dots Want to learn even more about how digital solutions can unlock the full potential of GLP-1 therapies

Global regulatory frameworksespecially the ICH S1 series guidelinesrequire structured carcinogenicity assessment: ICH S1A/S1B/S1C define when lifetime rodent studies are required Emphasis on hazard identification rather than direct human prediction Adoption of Weight-of-Evidence (WoE) approaches in ICH S1B(R1) The updated S1B(R1) guideline specifically encourages: Integration of mechanistic, exposure, and translational data Reduced reliance on 2-year rodent bioassays when justified Greater emphasis on human relevance and multi-factor evidence This shift reflects a broader regulatory evolution toward mechanism-based safety assessment rather than purely animal-driven hazard signals